Evidence map›Paper›PMID 34851968›Full record

ArticlePloS one2021

Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.

Esmail M Al-Ezzi, Zachary W Veitch, Samer H Salah, Theodorus H Van der Kwast, Tracy L Stockley, Shamini Selvarajah, Tong Zhang, Srikala S Sridhar, Adrian G Sacher, Nazanin Fallah-Rad and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Esmail M Al-EzziDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Zachary W VeitchDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Samer H SalahDivision of Medical Oncology and Hematology, King Hussain Cancer Center, Amman, Jordan.
Theodorus H Van der KwastDepartment of Pathology, Toronto General Hospital, Toronto, ON, Canada.
Tracy L StockleyDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Shamini SelvarajahDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Tong ZhangDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Srikala S SridharDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Adrian G SacherDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Nazanin Fallah-RadDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Girish S KulkarniDivision of Urologic Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Alexandre R ZlottaDivision of Urologic Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Antonio FinelliDivision of Urologic Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Aaron R HansenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0002-2363-8707
Princess Margaret Cancer Centre · CAUniversity Health Network · CAKing Hussein Cancer Center · JOToronto General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-schistosomiasis related-squamous cell carcinoma of urinary bladder (NSR-SCCUB) is a rare tumor subtype distinct from urothelial carcinoma (UC). Studies assessing molecular biomarkers in bladder cancer have generally focused on UC, and genomic data of NSR-SCCUB is limited. We aim to provide additional insight into the molecular underpinnings of this rare entity.

methodsNSR-SCCUB patients were identified retrospectively at Princess Margaret Cancer Centre between 2002 and 2017. Demographics, disease characteristics, therapeutic approaches, and outcomes were collected. Tissue samples were interrogated using the Oncomine Comprehensive Assay v3 (ThermoFisher). Kaplan-Meier method was used to estimate the disease-free survival and overall survival (OS).

resultsOverall, 11 patients with NSR-SCCUB were identified between 2002 and 2017 with adequate tissue samples. Median age was 71 years (45-86), predominantly male (63.6%). At time of diagnosis, 9 patients (81.8%) had muscle-invasive disease, 1 (9.1%) had non-muscle invasive, and 1 (9.1%) had advanced disease. Nine (81.8%) patients had radical cystectomy and pelvic lymph nodes dissection. Eight (72.7%) patients had pT3 or pT4 with N0, and 5 (45.5%) were grade 3. Median OS was 12.5 months (95% CI 7.7-17.2 months). Single nucleotide variants or insertion/deletions were identified in TP53, TERT, PIK3CA, PTEN, CREBBP, FBXW7, and FGFR3. Amplifications were found in CCND1, and EGFR.

conclusionsNSR-SCCUB has potentially actionable genomic alterations with anticancer agents and many of these aberrations are also seen in UC. The recruitment of NSR-SCCUB patients harboring such mutations should be considered in biomarker driven urinary bladder cancer studies.

Indexed as

MutationAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellClass I Phosphatidylinositol 3-KinasesCREB-Binding ProteinCyclin D1ErbB ReceptorsF-Box-WD Repeat-Containing Protein 7FemaleHumansMaleMiddle AgedPTEN PhosphohydrolaseReceptor, Fibroblast Growth Factor, Type 3Biomarkers, TumorCCND1 protein, humanClass I Phosphatidylinositol 3-KinasesCREB-Binding ProteinCREBBP protein, humanCyclin D1EGFR protein, humanErbB ReceptorsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanFGFR3 protein, humanPIK3CA protein, humanPTEN PhosphohydrolasePTEN protein, humanReceptor, Fibroblast Growth Factor, Type 3TelomeraseTERT protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID34851968
PMCPMC8635362
OpenAlexW3215100814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.